450 related articles for article (PubMed ID: 24342522)
1. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Lantinga MA; D'Agnolo HM; Casteleijn NF; de Fijter JW; Meijer E; Messchendorp AL; Peters DJ; Salih M; Spithoven EM; Soonawala D; Visser FW; Wetzels JF; Zietse R; Drenth JP; Gansevoort RT;
Drug Saf; 2017 Feb; 40(2):153-167. PubMed ID: 27995519
[TBL] [Abstract][Full Text] [Related]
4. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
6. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
8. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
9. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
10. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
11. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
[TBL] [Abstract][Full Text] [Related]
12. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
16. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
[TBL] [Abstract][Full Text] [Related]
17. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial.
Bais T; Meijer E; Kramers BJ; Vart P; Vervloet M; Salih M; Bammens B; Demoulin N; Todorova P; Müller RU; Halbritter J; Paliege A; Gall EC; Knebelmann B; Torra R; Ong ACM; Karet Frankl FE; Gansevoort RT
Trials; 2024 Feb; 25(1):120. PubMed ID: 38355627
[TBL] [Abstract][Full Text] [Related]
18. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
[TBL] [Abstract][Full Text] [Related]
19. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
20. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]